On Monday, Autolus Therapeutics plc ADR (NASDAQ: AUTL) opened higher 11.98% from the last session, before settling in for the closing price of $1.67. Price fluctuations for AUTL have ranged from $1.11 to $2.80 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 21.35% over the past five years. Company’s average yearly earnings per share was noted -12.14% at the time writing. With a float of $240.34 million, this company’s outstanding shares have now reached $266.14 million.
Autolus Therapeutics plc ADR (AUTL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 51.21%.
Autolus Therapeutics plc ADR (AUTL) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.09 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.24) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.49% during the next five years compared to 21.35% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Check out the current performance indicators for Autolus Therapeutics plc ADR (AUTL). In the past quarter, the stock posted a quick ratio of 5.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Autolus Therapeutics plc ADR (NASDAQ: AUTL) saw its 5-day average volume 2.32 million, a negative change from its year-to-date volume of 2.49 million. As of the previous 9 days, the stock’s Stochastic %D was 61.32%.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 50.76%, which indicates a significant decrease from 85.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0968 in the past 14 days, which was lower than the 0.1086 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4916, while its 200-day Moving Average is $1.7126. Nevertheless, the first resistance level for the watch stands at $1.9733 in the near term. At $2.0767, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.2133. If the price goes on to break the first support level at $1.7333, it is likely to go to the next support level at $1.5967. Assuming the price breaks the second support level, the third support level stands at $1.4933.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
There are currently 266,143K shares outstanding in the company with a market cap of 497.68 million. Presently, the company’s annual sales total 10,120 K according to its annual income of -220,660 K. Last quarter, the company’s sales amounted to 21,190 K and its income totaled -79,120 K.
